MDACC Study No:2012-0734 ( NCT No: NCT01807598)
Title:A study of brentuximab vedotin (SGN-35) in CD30-positive systemic mastocytosis +/- an associated hematological clonal
non-mast cell lineage disease (AHNMD)
Principal Investigator:Srdan Verstovsek
Treatment Agent:SGN-35
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the study drug Adcetris
(brentuximab vedotin) can help to control SM. The safety of this drug will
also be studied.

Brentuximab vedotin is designed to find a certain protein (CD30) on cancer
cells and bind to it. This may kill the cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:SGN-35
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Seattle Genetics
Stanford University
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults